Annual EBITDA
-$46.92 M
+$32.50 M+40.92%
December 31, 2023
Summary
- As of February 28, 2025, TBPH annual EBITDA is -$46.92 million, with the most recent change of +$32.50 million (+40.92%) on December 31, 2023.
- During the last 3 years, TBPH annual EBITDA has risen by +$240.91 million (+83.70%).
- TBPH annual EBITDA is now -641.92% below its all-time high of -$6.32 million, reached on December 31, 2012.
Performance
TBPH EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$9.42 M
+$4.18 M+30.71%
September 30, 2024
Summary
- As of February 28, 2025, TBPH quarterly EBITDA is -$9.42 million, with the most recent change of +$4.18 million (+30.71%) on September 30, 2024.
- Over the past year, TBPH quarterly EBITDA has stayed the same.
- TBPH quarterly EBITDA is now -216.60% below its all-time high of -$2.98 million, reached on December 31, 2023.
Performance
TBPH Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$34.59 M
-$3.38 M-10.85%
September 30, 2024
Summary
- As of February 28, 2025, TBPH TTM EBITDA is -$34.59 million, with the most recent change of -$3.38 million (-10.85%) on September 30, 2024.
- Over the past year, TBPH TTM EBITDA has stayed the same.
- TBPH TTM EBITDA is now -14.15% below its all-time high of -$30.30 million, reached on March 31, 2024.
Performance
TBPH TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TBPH EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +40.9% | 0.0% | 0.0% |
| 3 y3 years | +83.7% | 0.0% | 0.0% |
| 5 y5 years | +77.9% | +91.3% | +88.0% |
TBPH EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +81.1% | -216.6% | +82.7% | -14.2% | +83.5% |
| 5 y | 5-year | at high | +83.7% | -216.6% | +91.3% | -14.2% | +88.0% |
| alltime | all time | -641.9% | +83.7% | -216.6% | +91.3% | -14.2% | +88.0% |
Theravance Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.42 M(-30.7%) | -$34.59 M(+10.8%) |
| Jun 2024 | - | -$13.60 M(+58.2%) | -$31.20 M(+3.0%) |
| Mar 2024 | - | -$8.59 M(+188.8%) | -$30.30 M(-29.0%) |
| Dec 2023 | -$46.92 M(-40.9%) | -$2.98 M(-50.7%) | -$42.66 M(-17.0%) |
| Sep 2023 | - | -$6.04 M(-52.4%) | -$51.37 M(-11.5%) |
| Jun 2023 | - | -$12.70 M(-39.4%) | -$58.05 M(-9.4%) |
| Mar 2023 | - | -$20.95 M(+79.3%) | -$64.10 M(-18.9%) |
| Dec 2022 | -$79.42 M(-68.0%) | -$11.68 M(-8.1%) | -$79.05 M(-35.2%) |
| Sep 2022 | - | -$12.71 M(-32.2%) | -$121.91 M(-23.9%) |
| Jun 2022 | - | -$18.75 M(-47.8%) | -$160.21 M(-11.0%) |
| Mar 2022 | - | -$35.90 M(-34.2%) | -$180.05 M(-13.9%) |
| Dec 2021 | -$248.08 M(-13.8%) | -$54.55 M(+6.9%) | -$209.20 M(-20.4%) |
| Sep 2021 | - | -$51.01 M(+32.2%) | -$262.66 M(-3.3%) |
| Jun 2021 | - | -$38.60 M(-40.7%) | -$271.65 M(-3.8%) |
| Mar 2021 | - | -$65.05 M(-39.8%) | -$282.26 M(-1.9%) |
| Dec 2020 | -$287.82 M(+41.4%) | -$108.01 M(+80.0%) | -$287.82 M(+21.8%) |
| Sep 2020 | - | -$59.99 M(+21.9%) | -$236.23 M(+2.6%) |
| Jun 2020 | - | -$49.20 M(-30.3%) | -$230.23 M(+9.0%) |
| Mar 2020 | - | -$70.62 M(+25.2%) | -$211.25 M(+3.8%) |
| Dec 2019 | -$203.60 M(-4.2%) | -$56.41 M(+4.5%) | -$203.60 M(+4.0%) |
| Sep 2019 | - | -$54.00 M(+78.7%) | -$195.70 M(-1.7%) |
| Jun 2019 | - | -$30.22 M(-52.0%) | -$199.04 M(-6.8%) |
| Mar 2019 | - | -$62.97 M(+29.8%) | -$213.50 M(+0.5%) |
| Dec 2018 | -$212.44 M | -$48.51 M(-15.4%) | -$212.44 M(-11.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$57.34 M(+28.3%) | -$240.70 M(-2.3%) |
| Jun 2018 | - | -$44.68 M(-27.8%) | -$246.29 M(-6.8%) |
| Mar 2018 | - | -$61.91 M(-19.4%) | -$264.33 M(+2.0%) |
| Dec 2017 | -$259.14 M(+47.2%) | -$76.78 M(+22.0%) | -$259.14 M(+8.6%) |
| Sep 2017 | - | -$62.92 M(+0.3%) | -$238.54 M(+14.7%) |
| Jun 2017 | - | -$62.72 M(+10.6%) | -$207.98 M(+8.3%) |
| Mar 2017 | - | -$56.72 M(+0.9%) | -$192.00 M(+9.1%) |
| Dec 2016 | -$176.04 M(-1.3%) | -$56.19 M(+73.6%) | -$176.04 M(+1.0%) |
| Sep 2016 | - | -$32.36 M(-30.8%) | -$174.30 M(-5.4%) |
| Jun 2016 | - | -$46.73 M(+14.7%) | -$184.31 M(+1.2%) |
| Mar 2016 | - | -$40.76 M(-25.1%) | -$182.12 M(+2.2%) |
| Dec 2015 | -$178.28 M(-21.6%) | -$54.45 M(+28.5%) | -$178.28 M(-4.6%) |
| Sep 2015 | - | -$42.38 M(-4.9%) | -$186.94 M(-3.4%) |
| Jun 2015 | - | -$44.55 M(+20.7%) | -$193.55 M(-5.6%) |
| Mar 2015 | - | -$36.91 M(-41.5%) | -$205.03 M(-9.8%) |
| Dec 2014 | -$227.40 M(+48.0%) | -$63.11 M(+28.8%) | -$227.40 M(+9.5%) |
| Sep 2014 | - | -$48.99 M(-12.6%) | -$207.68 M(+4.2%) |
| Jun 2014 | - | -$56.02 M(-5.5%) | -$199.21 M(+9.8%) |
| Mar 2014 | - | -$59.29 M(+36.6%) | -$181.45 M(+18.1%) |
| Dec 2013 | -$153.63 M(+2329.3%) | -$43.39 M(+7.1%) | -$153.63 M(+39.4%) |
| Sep 2013 | - | -$40.52 M(+5.9%) | -$110.25 M(+58.1%) |
| Jun 2013 | - | -$38.25 M(+21.5%) | -$69.72 M(+121.5%) |
| Mar 2013 | - | -$31.47 M | -$31.47 M |
| Dec 2012 | -$6.32 M | - | - |
FAQ
- What is Theravance Biopharma annual EBITDA?
- What is the all time high annual EBITDA for Theravance Biopharma?
- What is Theravance Biopharma annual EBITDA year-on-year change?
- What is Theravance Biopharma quarterly EBITDA?
- What is the all time high quarterly EBITDA for Theravance Biopharma?
- What is Theravance Biopharma quarterly EBITDA year-on-year change?
- What is Theravance Biopharma TTM EBITDA?
- What is the all time high TTM EBITDA for Theravance Biopharma?
- What is Theravance Biopharma TTM EBITDA year-on-year change?
What is Theravance Biopharma annual EBITDA?
The current annual EBITDA of TBPH is -$46.92 M
What is the all time high annual EBITDA for Theravance Biopharma?
Theravance Biopharma all-time high annual EBITDA is -$6.32 M
What is Theravance Biopharma annual EBITDA year-on-year change?
Over the past year, TBPH annual EBITDA has changed by +$32.50 M (+40.92%)
What is Theravance Biopharma quarterly EBITDA?
The current quarterly EBITDA of TBPH is -$9.42 M
What is the all time high quarterly EBITDA for Theravance Biopharma?
Theravance Biopharma all-time high quarterly EBITDA is -$2.98 M
What is Theravance Biopharma quarterly EBITDA year-on-year change?
Over the past year, TBPH quarterly EBITDA has changed by $0.00 (0.00%)
What is Theravance Biopharma TTM EBITDA?
The current TTM EBITDA of TBPH is -$34.59 M
What is the all time high TTM EBITDA for Theravance Biopharma?
Theravance Biopharma all-time high TTM EBITDA is -$30.30 M
What is Theravance Biopharma TTM EBITDA year-on-year change?
Over the past year, TBPH TTM EBITDA has changed by $0.00 (0.00%)